Brain Metastasis – Pipeline Review, 2019

Brain Metastasis is a tumor associated with brain that starts in another part of the body and later spreads to the brain. Brain metastasis is secondary brain tumors and are more common than primary brain cancer. The types of cancer that are likely to spread to the brain are lung, breast, colon, melanoma, and kidney. As the brain metastatic tumor grows, it creates pressure and changes the function of the surrounding brain tissue. Symptoms include headache, swelling, vomiting, increasing memory problems, dizziness, and others. 

Management and treatment for brain metastasis include medication, surgery, chemotherapy, targeted therapy, and radiation. Corticosteroids and anticonvulsants are generally prescribed for the treatment of brain tumors. Drugs like Bevacizumab, Carmustine, and Lomustine, are the drugs used to treat glioblastoma, high-grade glioblastoma, and other brain tumors.

Pharmaceutical companies, along with various research institutes, have been focusing on studying and developing new treatment options for brain metastasis. For instance; LY3381916, studied by Eli Lilly and Company is currently in phase-1 clinical trials for the study of safety and efficacy of LY3381916 drug when administered alone or with combination with other drugs in patients with brain metastasis.

At present around 53% of the pipeline candidates for brain metastasis are in the phase-2 clinical stage. Maximum studies are sponsored by research institutes.

Report Description

The report on ‘Brain Metastasis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Brain Metastasis The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Brain Metastasis.

The report on ‘Brain Metastasis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Brain Metastasis.


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Brain Metastasis.


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary.